Earlier today Abzena confirmed that it had successfully completed a technology transfer and scalability evaluation using the Synaffix‘s technologies of GlycoConnect™, site-specific antibody-drug conjugation and HydraSpace™, polar spacer technologies.
Synaffix is a Dutch biotechnology company focused on the advancement of its clinical-stage technology for the development of best-in-class antibody-drug conjugates with an expanded therapeutic index (TI) and improved manufacturability.
GlycoConnect™ is Synaffix’s conjugation technology that exploits the native glycan for site-specific and stable payload attachment. The technology enables the design of complex biological drugs without the need for prior genetic modification and with specificity and precision similar to what is used to design modern small molecule drugs. HydraSpace™ is Synaffix’s compact and highly polar spacer technology.
Both technologies can be applied directly to any existing antibody without any protein engineering and are compatible with all ADC payload classes. Based on ongoing research, Synaffix’s technology help drug developers and manufacturers to consistently generate ADCs that are more effective and better tolerated when compared to existing ADC conjugation technologies.
Technology transfer is a complex and challenging process designed to confirm that no or minimal changes are made to a bio-pharmaceutical development process original developed by a 3rd party at a different site. They require substantial resources, technical know-how, and organizational skills in both ‘sending’ and ‘receiving’ units.
The familiarity and ability to use these specific technologies adds to Abzena’s abilities in process development and GMP manufacturing of linkers and payloads for antibody-drug conjugates. Following the technology transfer Abzena can now ramp up a number of specific ADC projects using Synaffix technology
“We believe in patient first drug development. Our expertise and experience with Synaffix GlycoConnect™ and HydraSpace™ technology further advances our leadership across multiple platforms in ADC,” said Jonathan Goldman, MD, the Chief Executive Officer of Abzena.
“We look forward to supporting our customers as they leverage Synaffix technology to rapidly advance ADCs from IND stage into early clinical development,” Goldman concluded.